Paul Industries delivers cleanroom construction for biotech & bioprocessing as a single-source supplier and installer. We design, fabricate, install, passivate, and validate cleanroom construction – the ISO 14644-classified controlled environments, HVAC, and HEPA systems that keep aseptic and controlled processes in compliance – built to the standards your process and your auditors require.
What biotech & bioprocessing need from cleanroom construction
Bioprocessing adds a layer of complexity beyond traditional pharma: living cell cultures, single-use and stainless hybrid trains, bioreactors, and aseptic fill-finish. Cell and gene therapy suites push classification and segregation even harder. The water, piping, and cleanroom systems supporting biologics have to protect sterility and product integrity at every step.
For this work, that means aseptic processing, single-use/stainless integration, WFI and clean steam for bioreactors, and Grade A/B cleanroom segregation – not as an afterthought, but engineered in from the first drawing.
What we deliver
- ISO 14644 Class 5-8 (Grade A-D) modular hardwall and softwall cleanrooms
- HVAC, HEPA filtration, pressure cascade, and environmental monitoring designed to hold classification
- Gowning rooms, airlocks/pass-throughs, and material/personnel flow that satisfy GMP inspection
- Wall, ceiling, flooring, and utility integration coordinated with your process equipment
- Commissioning, certification, and as-built documentation for the finished space
One accountable partner
Most biotech projects get split between an equipment supplier and an install contractor – and the validation burden falls in the gap between them. Paul Industries closes that gap by self-performing the whole scope, from supply through documented turnover.
Related: Cleanroom Construction services · Biotech & Bioprocessing solutions · Request a quote
Frequently asked questions
What cleanroom class does biotech manufacturing require?
Biotech grades depend on the step. Aseptic cell culture and fill zones are often ISO 5 within an ISO 7 background, while upstream and support areas may be ISO 8. The risk of introducing microbes to living cultures drives the classification, which Paul Industries sets against each unit operation.
Why are cleanrooms critical for cell and gene therapy?
Cell and gene therapies are often patient-specific, cannot be terminally sterilized, and are processed open or semi-open. That makes the cleanroom environment the primary barrier against contamination that could ruin a single irreplaceable batch, so airflow, pressurization, and segregation are engineered tightly.
How do biotech cleanrooms handle live biological materials?
Through containment as well as cleanliness, which is a different engineering problem from a conventional cleanroom. A room holding live organisms has to protect the operator and the environment outward, while a classified room protects the product inward, and those two pull room pressure in opposite directions. The usual resolution is a cascade with a positive-pressure airlock between the suite and the corridor, so neither direction leaks directly. Work with recombinant material also answers to an Institutional Biosafety Committee under the NIH Guidelines.
What is the difference between upstream and downstream cleanroom needs in biotech?
Upstream cell culture and fermentation emphasize sterility and closed processing, while downstream purification and fill often require the cleanest aseptic zones. Paul Industries classifies each area to its actual risk rather than blanketing the whole facility at one grade, controlling cost and complexity.
How does single-use technology affect biotech cleanroom design?
Single-use bioreactors and assemblies shift some sterility control into disposable closed systems, which can relax the surrounding room grade for certain steps. The cleanroom design still must support aseptic connections and material flow, so Paul Industries integrates single-use workflows into the layout and utilities.
What contamination risks are unique to biotech cleanrooms?
Cross-contamination between biological products, rather than particulate alone. Cell lines, viral vectors and recombinant organisms can contaminate one another in ways a particle counter will never detect, so segregation, unidirectional material and personnel flow, and changeover controls matter more than achieving a lower ISO class. The second risk is that live material shed in a room is not removed by the same measures that clear particles, which is why surface and active air microbial monitoring sits alongside particle classification.
Do biotech cleanrooms need containment as well as cleanliness?
Frequently yes, and the two must never be budgeted from the same benchmark. A BSL-2 suite is close to a conventional cleanroom with biological safety cabinets providing primary containment. A BSL-3 suite is a different scale entirely, typically 1,400 to 3,200 dollars per square foot against 240 to 540 for ISO 7, because of exhaust HEPA filtration, tested envelope integrity, redundancy, alarms and a far heavier commissioning burden. Annual containment recertification then runs 18,000 to 70,000 dollars per suite.
How are biotech cleanrooms validated?
On two tracks that run in parallel. Classification follows ISO 14644 with particle counts in the specified occupancy state, airflow velocity and volume, pressure differentials against the design cascade, installed filter leakage testing and recovery testing. Containment, where it applies, is verified separately: directional airflow and cascade stability under fault conditions, envelope integrity, exhaust HEPA integrity, interlock and alarm function, and where the design requires it a gaseous decontamination validation. Biological safety cabinets are certified to NSF 49.
What HVAC considerations matter most for biotech suites?
Biotech HVAC manages air changes, humidity for product and microbial control, and the pressure cascade between clean and contained zones, often with once-through air where recirculation is not safe. Sizing this system correctly is central to holding both cleanliness and containment.
Can Paul Industries build biotech cleanrooms nationwide?
Yes, nationwide from Kilmarnock, Virginia, as planned projects with dates confirmed at quotation. On biotech cleanroom work the front-end constraint is normally air handling equipment lead time and the back-end constraint is commissioning and qualification, neither of which changes with contractor location. Where a project sits on a federal or federally adjacent site, personnel screening and site access can add weeks to mobilization, and that is worth establishing at enquiry stage rather than after award.
How do biotech cleanrooms support aseptic connections?
The design provides the clean background, laminar-flow protection, and material flow that let operators or single-use systems make aseptic connections safely. Pass-throughs, biosafety cabinets, and isolators may sit within the room, and the cleanroom must maintain grade around these critical interventions.
What high-purity utilities do biotech cleanrooms depend on?
Biotech processes need WFI and USP purified water for media, buffers, and cleaning, plus clean steam and sanitary piping. Paul Industries builds the cleanroom and these utilities together, so the water and steam feeding the suite meet the same cGMP standards as the room.
How does biotech cleanroom design handle multi-product facilities?
By designing for changeover rather than for the cleanest single state. Multi-product biotech suites succeed or fail on segregation: separate processing rooms with their own airlocks, unidirectional flow that does not cross, dedicated or validated-clean transfer items, and a cascade that holds when doors are used as they actually will be. Shared equipment then carries a cleaning validation burden of 20,000 to 92,000 dollars per product, which is frequently the argument for dedicating trains rather than sharing them.
What causes biotech cleanroom excursions and how are they addressed?
Look at the envelope and the cascade before the filters. Classification excursions are more often caused by leakage, pressure drift or gowning practice than by filter degradation. Verify the cascade against design, run filter integrity testing to distinguish a leaking filter from a leaking frame seal, inspect doors, ceiling grid, penetrations and pass-throughs, then perform recovery testing. A microbial excursion is a separate investigation: identify the organism, since a skin flora isolate points to gowning while an environmental species points to the envelope or to water.
How does biotech cleanroom design scale from clinical to commercial?
Clinical-scale suites are smaller and more flexible, while commercial production adds throughput, redundancy, and tighter segregation. Forward-looking design leaves HVAC, utility, and space headroom so a facility can scale up. Paul Industries can build in that capacity when scale-up is anticipated.
How do we start a biotech cleanroom project?
Start with what will actually happen in the room and what organisms are involved, because containment level and segregation strategy follow from that and they determine the whole design. Then the shell constraints: floor-to-floor height, available air handling capacity and shaft space, and whether exhaust can be routed and treated. If recombinant material is involved, register the work with your Institutional Biosafety Committee early, since that review runs on its own timeline and does not align with construction.
What biotech requirements do you build to?
ISO 14644 for classification and monitoring, with EU GMP Annex 1 where sterile product is supplied into Europe, which is materially more prescriptive on contamination control strategy. 21 CFR 211 for the quality system and 21 CFR 610 where the product is a biologic. For containment, the NIH Guidelines and your Institutional Biosafety Committee determination set the biosafety level, with NSF 49 governing biological safety cabinet certification. Process systems within the suite follow ASME BPE and the USP water monographs.
Get a single-source quote
Paul Industries designs, fabricates, installs, passivates, and validates – one accountable partner instead of a vendor plus a contractor plus a validation firm. Tell us about your project and we will scope it.
What ISO class do biotech and bioprocessing cleanrooms need?
| Requirement | What it means |
|---|---|
| Aseptic operations | ISO 5 where product is exposed |
| Bioreactor and harvest suites | Commonly ISO 7 or 8 depending on containment and closure |
| Buffer and media preparation | ISO 7 or 8 |
| Containment direction | May be NEGATIVE pressure where the organism must be contained — the opposite of product protection |
| Biosafety level | BSL containment drives room design, waste handling and exhaust treatment |
| Waste | Validated inactivation before discharge |
| Governing standards | ISO 14644 plus NIH Guidelines and institutional biosafety review |
| Qualification | Certification plus IQ/OQ/PQ |
More questions we are asked
Do you handle validation, or just installation?
Both, and for biotech cleanrooms the distinction matters more than in most trades because classification is a system property. A contractor who installs the envelope but not the air, or the air but not the envelope, cannot be held to a particle count result, since the room passes or fails on envelope tightness, air change rate, pressure cascade and filter integrity together. Paul Industries performs the build and then the ISO 14644 classification, airflow, pressurization, HEPA scan testing and recovery testing, with IQ, OQ and PQ documentation, plus smoke studies and microbial monitoring plan support for aseptic areas. One party is therefore accountable for the number the room actually achieves.
Can you take a project from design through startup?
Yes, and on a biotech project the reason it matters is the qualification tail rather than the construction. A cleanroom is not usable at mechanical completion; it is usable once classified, qualified and, for aseptic areas, once the environmental monitoring program has established a baseline. Splitting design, build and qualification across parties means the schedule has three handovers, and the last one lands exactly where the program has no slack. Holding it under one contract means the commissioning tests are planned during design, the turnover package is assembled as work proceeds rather than reconstructed at the end, and a failed test is corrected by the party that built the thing.
Best companies for biotech facility buildout services in the US
Biotech buildouts fail at seams rather than at trades, so screen on scope boundaries. The recurring gaps: who owns the pressure cascade across the whole suite rather than room by room; who is accountable when a compendial water point of use inside a cleanroom fails sampling, since that is simultaneously a piping detail and a room integrity detail; who assembles the turnover package and when; and who corrects a failed qualification test. Ask each candidate to state in writing which of those they own. Firms that describe themselves as biotech specialists but hold only one trade will have honest answers to none of them. Paul Industries delivers envelope, mechanical, process piping, water systems, passivation and qualification under one contract nationwide.
Best practices for designing a BSL-2 lab facility
BSL-2 is a practices-and-equipment standard more than a construction one, which is where designs commonly over- or under-build. The core requirements are a lab separable from general traffic with a self-closing lockable door, handwashing at the exit, work surfaces impervious and resistant to the chemicals used, a Class II biological safety cabinet for procedures generating aerosols, an autoclave accessible for decontaminating waste, and eyewash provision. Directional inward airflow is recommended rather than mandated at BSL-2, and no room sealing for decontamination is required. Where the work involves recombinant material, NIH Guidelines and Institutional Biosafety Committee registration apply and frequently drive more than the biosafety level itself. Designing to BSL-3 by default wastes substantial capital and running cost.
Best practices for designing a cGMP compliant cell and gene therapy manufacturing plant
Design around flows and segregation before classification. Autologous processing means many small batches with a high risk of mix-up, so chain-of-identity and chain-of-custody drive layout, material transfer and labelling more than particle counts do. Closed and functionally closed processing reduces the required room grade substantially, which is the single largest cost lever available: processing in a closed system inside a Grade C room is far cheaper to build and run than open processing in Grade B. Plan suites for reconfiguration, since programs change faster than facilities. Provide segregation between incoming patient material and finished product routes. And where viral vectors are involved, reconcile the containment requirement with the product-protection requirement early, because they pull pressure in opposite directions.
How to choose a cell and gene therapy facility for clinical trial production?
Whether you are selecting a contract facility or assessing your own, the questions are the same. What room grades are available and can the process be run closed, since that determines both cost and capacity. How is chain of identity maintained from patient material through to release, and what physically prevents a mix-up between concurrent batches. What is the suite turnaround time between batches, because that sets real throughput far more than nominal capacity. Is there segregation between viral vector production and downstream processing. What is the environmental monitoring history and how are excursions handled. And crucially, what is the release testing turnaround, since for autologous therapies the patient is waiting and a slow release path is a clinical problem rather than an operational one.